1. Adjuvant denosumab in early breast cancer (D-CARE): an international, multicentre, randomised, controlled, phase 3 trial;Coleman;Lancet Oncol.,2020
2. Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer (ABCSG-18): disease-free survival results from a randomised, double-blind, placebo-controlled, phase 3 trial;Gnant;Lancet Oncol.,2019
3. E.B.C.T.C. Group, Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials, The Lancet 386(10001) (2015) 1353-1361.
4. Use of adjuvant bisphosphonates and other bone-modifying agents in breast cancer: a cancer care Ontario and American society of clinical oncology clinical practice guideline;Dhesy-Thind;J. Clin. Oncol.,2017
5. Management of Aromatase Inhibitor-Associated Bone Loss (AIBL) in postmenopausal women with hormone sensitive breast cancer: Joint position statement of the IOF CABS, ECTS, IEG, ESCEO IMS, and SIOG;Hadji;J. Bone Oncol.,2017